Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer by Rebbeck, Tr et al.
Association of Type and Location of BRCA1 and BRCA2 
Mutations With Risk of Breast and Ovarian Cancer
Timothy R. Rebbeck, PhD, Nandita Mitra, PhD, Fei Wan, MS, Olga M. Sinilnikova, PhD†, Sue 
Healey, Lesley McGuffog, Sylvie Mazoyer, PhD, Georgia Chenevix-Trench, PhD, Douglas F. 
Easton, PhD, Antonis C. Antoniou, PhD, Katherine L. Nathanson, MD, and the CIMBA 
Consortium
Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, 
Philadelphia (Rebbeck, Nathanson); Center for Clinical Epidemiology and Biostatistics, Perelman 
School of Medicine at the University of Pennsylvania, Philadelphia (Rebbeck, Mitra, Wan); Centre 
de Recherche en Cancérologie de Lyon, UMR Inserm, Centre Léon Bérard, Lyon, France 
(Sinilnikova, Mazoyer); Department of Genetics and Computational Biology, Queensland Institute 
of Medical Research, Brisbane, Australia (Healey, Chenevix-Trench); Centre for Cancer Genetic 
Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 
Cambridge, United Kingdom (McGuffog, Easton, Antoniou); Department of Medicine, Perelman 
School of Medicine at the University of Pennsylvania, Philadelphia (Nathanson)
Abstract
IMPORTANCE—Limited information about the relationship between specific mutations in 
BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists.
OBJECTIVE—To identify mutation-specific cancer risks for carriers of BRCA1/2.
DESIGN, SETTING, AND PARTICIPANTS—Observational study of women who were 
ascertained between 1937 and 2011 (median, 1999) and found to carry disease-associated BRCA1 
or BRCA2 mutations. The international sample comprised 19 581 carriers of BRCA1 mutations 
and 11 900 carriers of BRCA2 mutations from 55 centers in 33 countries on 6 continents. We 
estimated hazard ratios for breast and ovarian cancer based on mutation type, function, and 
nucleotide position. We also estimated RHR, the ratio of breast vs ovarian cancer hazard ratios. A 
value of RHR greater than 1 indicated elevated breast cancer risk; a value of RHR less than 1 
indicated elevated ovarian cancer risk.
EXPOSURES—Mutations of BRCA1 or BRCA2.
MAIN OUTCOMES AND MEASURES—Breast and ovarian cancer risks.
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RESULTS—Among BRCA1 mutation carriers, 9052 women (46%) were diagnosed with breast 
cancer, 2317 (12%) with ovarian cancer, 1041 (5%) with breast and ovarian cancer, and 7171 
(37%) without cancer. Among BRCA2 mutation carriers, 6180 women (52%) were diagnosed with 
breast cancer, 682 (6%) with ovarian cancer, 272 (2%) with breast and ovarian cancer, and 4766 
(40%) without cancer. In BRCA1, we identified 3 breast cancer cluster regions (BCCRs) located at 
c.179 to c.505 (BCCR1; RHR = 1.46; 95% CI, 1.22–1.74; P = 2 × 10−6), c.4328 to c.4945 
(BCCR2; RHR = 1.34; 95% CI, 1.01–1.78; P = .04), and c. 5261 to c.5563 (BCCR23, RHR = 
1.38; 95% CI, 1.22–1.55; P = 6 × 10−9). We also identified an ovarian cancer cluster region 
(OCCR) from c.1380 to c.4062 (approximately exon 11) with RHR = 0.62 (95% CI, 0.56–0.70; P 
= 9 × 10−17). In BRCA2, we observed multiple BCCRs spanning c.1 to c.596 (BCCR1; RHR = 
1.71; 95% CI, 1.06–2.78; P = .03), c.772 to c.1806 (BCCR13; RHR = 1.63; 95% CI, 1.10–2.40; P 
= .01), and c.7394 to c.8904 (BCCR2; RHR = 2.31; 95% CI, 1.69–3.16; P = .00002). We also 
identified 3 OCCRs: the first (OCCR1) spanned c.3249 to c.5681 that was adjacent to c.5946delT 
(6174delT; RHR = 0.51; 95% CI, 0.44–0.60; P = 6 × 10−17). The second OCCR spanned c.6645 to 
c.7471 (OCCR2; RHR = 0.57; 95% CI, 0.41–0.80; P = .001). Mutations conferring nonsense-
mediated decay were associated with differential breast or ovarian cancer risks and an earlier age 
of breast cancer diagnosis for both BRCA1 and BRCA2 mutation carriers.
CONCLUSIONS AND RELEVANCE—Breast and ovarian cancer risks varied by type and 
location of BRCA1/2 mutations. With appropriate validation, these data may have implications for 
risk assessment and cancer prevention decision making for carriers of BRCA1 and BRCA2 
mutations.
Women who have inherited mutations in BRCA1 (17q21, chromosome 17: base pairs 
43,044,294 to 43,125,482) or BRCA2 (13q12.3, chromosome 13: base pairs 32,315,479 to 
32,399,671) have an increased risk of breast and ovarian cancers.1,2 Little is known about 
how cancer risks differ by BRCA1 or BRCA2 (BRCA1/2) mutation type. An “ovarian cancer 
cluster region” (OCCR) has been reported in both BRCA1 and BRCA2 using small sample 
sets. For BRCA1, initially mutations after exon 11 were associated with a 20% lower ovarian 
cancer risk than mutations in exons 1 through 11.3 Following that observation, Thompson et 
al4 reported an increased risk of ovarian vs breast cancer specifically was associated with 
mutations in the central portion of exon 11. This association was attributed to both a 
decrease in breast cancer risk and an increase in ovarian cancer risk in this region. Mutations 
in exon 11 of BRCA2 also have been associated with higher ovarian vs breast cancer risk 
than in other regions of the gene.5 It was hypothesized that this risk variation might be 
explained by the failure of BRCA1/2 exon 11 truncating mutations to trigger nonsense-
mediated messenger RNA (mRNA) decay (NMD) because of their extremely large size, 
contrary to truncating mutations in smaller exons. However, this postulate was not supported 
by the measures of the relative amounts of mRNA transcript encoded by BRCA1/2 alleles.6,7 
Murine models of different mutations in BRCA1/2 also suggest that genotype-phenotype 
correlations exist.8,9 To our knowledge, no study has reported whether BRCA1/2 mutation 
type is associated with differences in breast and ovarian cancer risk. Thus, we evaluated 
whether BRCA1 and BRCA2 mutation type or location is associated with variation in breast 
and ovarian cancer risk.
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Methods
The Consortium of Investigators of Modifiers of BRCA (CIMBA) initiative is an 
international collaboration of centers on 6 continents that has collected information about 
carriers of disease-associated BRCA1 and BRCA2 mutations with associated clinical, risk 
factor, and genetic data.10 All carriers participated in clinical assessment or research studies 
at the host institutions after providing informed consent under protocols approved by 
institutional review boards. For some individuals, ascertainment date reflects the earliest 
date at which they came to the attention of a clinician or research investigator (eg, when they 
were first seen in a clinic), even though their research participation, genetic testing, and 
research data collection may have occurred many years later. Fifty-five centers and multi-
center consortia (eTable 1 in the Supplement) in 33 countries submitted deidentified data 
that met the CIMBA inclusion criteria.10 Study eligibility criteria included carriage of a 
disease-associated mutation and clinical data necessary to estimate hazard ratios (ie, cancer 
diagnosis, ascertainment and follow-up dates). Women were excluded if they carried both a 
BRCA1 and BRCA2 mutation (n = 84).
No races/ethnicities were excluded from this study. All races/ethnicities were included in 
this report to provide maximal generalizability of results for populations who may be 
undergoing genetic testing and counseling. All race/ethnicity designations were based on 
self-report. Race/ethnicity data were collected across the various centers using either fixed 
categories or open-ended questions.
Mutation Classification
Only carriers with clearly pathogenic BRCA1/2 mutations were included in this analysis. 
Pathogenic mutations were defined as (1) mutations generating a premature termination 
codon, except variants generating a premature termination codon in exon 27 after codon 
3010 of BRCA211; (2) large in-frame deletions that span 1 or more exons; and (3) deletions 
of transcription regulatory regions (promoter and/or first exon) expected to cause lack of 
expression of mutant allele. We also included missense variants considered pathogenic by 
the Breast Cancer Information Core committee or published variants classified as pathogenic 
using multifactorial likelihood approaches.12,13 Mutations are described here using the 
Human Genome Variation Society nomenclature in which the nucleotide numbering is from 
the A of the ATG translation initiator codon, and use the c.XXX numbering convention 
(eAppendix 1 in the Supplement).
Creation of Mutation Groups for Analysis
Mutation Bins—To identify segments across the intronic and exonic regions of the 
BRCA1 or BRCA2 genes associated with different breast vs ovarian cancer risks, we created 
bins of mutations by base pair location (Figure 1). We divided the genomic regions of both 
genes to create bins of genomic sequence that contained all deleterious mutations regardless 
of category or function. Bins were constructed by using an algorithm in which each bin 
contained approximately equal numbers of participants with bin length defined by distance 
in base pairs. We excluded large genomic rearrangements from this analysis as those 
mutations span multiple bins and also undertook a subset analysis with and without missense 
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mutations. The resulting bins are presented in Figure 2 and eTable 2 in the Supplement for 
BRCA1 and Figure 3 and eTable 3 in the Supplement for BRCA2.
Mutation Type and Functional Domains—Mutations were grouped by type and 
function as frame shift, nonsense, missense, splice site, and then by in-frame and out-of-
frame. Mutation groups included individuals who carried in-frame deletions, nonsplice out-
of-frame deletions, and out-of-frame deletions. Missense mutations in BRCA1 were grouped 
into those within the RING14,15 and BRCT domains.16–19 Only 17 BRCA2 carriers (0.1%) 
had missense mutations classified as pathogenic; these were removed from the analysis 
because the sample size was too small to provide statistically meaningful inferences. 
Comparisons also were made of mutations predicted not to lead to NMD vs those that do 
lead to NMD. Mutations predicted not to cause NMD were defined as those that lead to a 
stop codon within 50 nucleotides before or within the last exon.20 In BRCA1, a subgroup 
including premature termination codons before c.297, presumed to allow reinitiation of 
translation at the AUG at that site, was examined separately.21 Premature termination 
codons refer to all mutations leading to a truncated open reading frame. Putative functional 
domains in BRCA1 and BRCA2 were defined using the boundaries in the Pfam database.22 
We also identified reported domains in BRCA1 or BRCA2 that are involved in binding 
putative proteins.
Statistical Analysis
The primary outcomes of interest were diagnosis of ovarian cancer or breast cancer. For 
ovarian cancer, observations were censored at the earliest of the following outcomes: 
bilateral risk-reducing salpingo-oophorectomy, death, or having reached the end of follow-
up without an ovarian cancer or other censoring event. In women with both breast and 
ovarian cancer diagnoses, prior breast cancer diagnoses were ignored in the analysis of 
ovarian cancer. Time to event was computed from birth to age at first ovarian cancer 
diagnosis or age at censoring. For the primary event of breast cancer, observations were 
censored at the earliest of the following outcomes: ovarian cancer, risk-reducing salpingo-
oophorectomy, risk-reducing mastectomy, death, or having reached the end of follow-up 
without a cancer or other censoring event. Time to event was computed from birth to age at 
first cancer diagnosis or age at censoring. To account for intracluster dependence due to 
multiple individuals from the same family, a robust sandwich variance estimate was 
specified in Cox proportional hazards models.23 All analyses were undertaken in BRCA1 
and BRCA2 mutation carriers separately. The proportional hazards assumption was tested 
using log(-log) plots and Schoenfeld residuals.
Our analyses assessed the relationship of mutation groups with cancer risk. First, we used 
mutation bins to evaluate whether there is evidence to support the previous report of an 
OCCR3,5 and whether breast cancer cluster regions (BCCRs) may exist. To assess whether 
specific genomic regions of these genes were associated with greater breast vs ovarian 
cancer risk, we computed the hazard ratio of breast cancer, the hazard ratio of ovarian 
cancer, and a statistic RHR, defined as the ratio of breast vs ovarian cancer hazard ratio 
estimates. Values of RHR greater than 1 indicate elevated breast cancer risk; values of RHR 
less than 1 indicate elevated ovarian cancer risk. We evaluated bins of mutations across the 
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span of BRCA1 or BRCA2 compared with all other mutations not contained in that bin by 
fitting a multiple correlated outcomes model stratified by cancer site.24 This approach 
allowed us to achieve 2 goals: first, to estimate the correlation between ovarian and breast 
cancer outcomes within an individual, and second, to provide an estimate of the RHR 
(estimated via an interaction term between cancer site and mutation bin) with the correct 
confidence interval using robust sandwich variance estimates to account for the correlation 
between outcomes within a woman. All analyses were adjusted for birth year and race, 
stratified by center, and controlled for clustering within family.
Second, we compared each mutation type or functional group against a common reference 
group. The use of a common reference group allowed us to compare hazard ratio estimates 
across different mutation classes. For both BRCA1 and BRCA2, we chose exon 11 nonsense 
mutations as the common reference group. Exon 11 nonsense mutations are common in 
diverse ethnic backgrounds and have been demonstrated to have the same biological effect, 
leading to NMD.25
Approximate cancer risks to age 70 years for specific mutation classes were derived from 
the relative risk estimates. For BRCA1 and BRCA2, estimated lifetime breast cancer 
penetrances were assumed to be 59% and 51% and ovarian cancer penetrance 34% and 11%, 
respectively.26 Mutation-specific penetrance estimates were derived using the method 
presented in eAppendix 2 in the Supplement.
Statistical tests were judged significant based on 2-sided hypothesis tests with P < .05. All P 
values were corrected for multiple hypothesis testing within each table of results by 
controlling the false discovery rate (FDR) using the method of Benjamini and Hochberg.27 
Analyses were conducted in SAS version 9 (SAS Institute) or R version 2.7.2 (R Foundation 
for Statistical Computing).
Results
A total of 19 581 female carriers of BRCA1 mutations and 11 900 carriers of BRCA2 
mutations were eligible for inclusion in this study. Table 1 reports the distribution of dates 
of ascertainment to the study as well as time from ascertainment to cancer diagnosis or 
censoring, as used in the survival analysis models reported in this section. Mean age of 
breast cancer diagnosis was 39.9 years in BRCA1 mutation carriers and 42.8 years in BRCA2 
mutation carriers. Mean age of ovarian cancer diagnosis was 50.0 years in BRCA1 mutation 
carriers and 54.5 years in BRCA2 mutation carriers. The 3 ovarian cancer cases diagnosed 
before age 18 years were germ cell tumors and included in the analysis (Table 1). Of note, 
all analyses also were undertaken excluding these 3 cases and there was no difference in the 
results. The majority of the sample consisted of white women for both BRCA1 and BRCA2 
mutation carriers: 92% to 93% white, including 8% to 9% Jewish women. Both BRCA1 and 
BRCA2 mutation carriers had a median parity of 2.0 live births and age at menarche of 13 
years. Median age at menopause was 44 years in BRCA1 and 46 years in BRCA2 mutation 
carriers, reflecting in part the use of preventive surgeries.
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BRCA1: Breast and Ovarian Cancer Cluster Regions
We observed an OCCR bounded by c.1380 and c.4062 (Figure 2), suggesting a relative 
decrease in breast relative to ovarian cancer risk (RHR = 0.62; 95% CI, 0.56–0.70; FDR-
corrected P = 9 × 10−17). This estimate was obtained by considering all mutations across 
multiple bins spanning the OCCR. The OCCR is explained by both a relative decrease in 
breast cancer risk and a relative increase in ovarian cancer risk (eTable 2 in the 
Supplement), which was statistically significant in bins 9, 11–13, 15–16, and 23 (Figure 2). 
The OCCR extends further 53 of the previously reported OCCR, which was defined by the 
interval c.2282 to c.4071.3 The OCCR is entirely contained within exon 11 (c.670-c.4096) 
with bins 6 and 23 being approximately coincident with the boundaries of the exon.
We also observed a relative increase in breast cancer risk and a relative decrease in ovarian 
cancer risk for mutations occurring in the 53 and 33 regions of BRCA1, potentially defining 
2 BCCRs (Figure 2). BCCR1 mutations within bins 4–5 (c.179-c.505) were associated with 
excess risks of breast vs ovarian cancer (eTable 2 in the Supplement) and lie within the 33 
region of the RING domain (c.72-c.192). Mutations in the BCCR1 were associated with a 
relative increase in breast cancer risk relative to ovarian cancer risk (RHR = 1.46; 95% CI, 
1.22–1.74; FDR-corrected P = 2 × 10−6). When all mutations in the RING domain were 
considered together as compared with all others, they were associated with a significant 
increase in breast cancer risk (HR = 1.13; 95% CI, 1.02–1.26) and a significant decrease in 
ovarian cancer risk (HR = 0.81; 95% CI, 0.67–0.97). Bin 2, which contains only the founder 
mutation BRCA1 c.68_69delAG (185delAG), did not provide statistically significant 
evidence for elevated breast vs ovarian cancer risks, suggesting that this mutation is 
associated with relatively equivalent risks of both cancers.
Mutations in bins 26 and 29–30 in the 33 region of BRCA1 also provided evidence for 
additional BCCRs. BCCR2 was associated with an increase in breast cancer relative to 
ovarian cancer risk (RHR = 1.34; 95% CI, 1.01–1.78; P = .04) bounded by c.4328 and c.
4945. The second segment of this BCCR (denoted BCCR23) includes the BRCT domains (c.
4926-c.5169 and c.5268-c.5526) and was associated with a relative excess of breast vs 
ovarian cancers (RHR = 1.38; 95% CI, 1.22–1.55; P = 6 × 10−9) (Figure 2). In the BRCT 
domains, the preponderance of mutations was missense, not expected to trigger NMD. This 
region also includes bin 29, which contains only the BRCA1 c.5266dupC (5382insC) 
mutation, which also is not predicted to lead to NMD as it introduces a premature 
termination codon in the last exon.6 In bin 30, BRCA1 c.5277 + 1G>A, a common splice site 
mutation in the Netherlands, is observed and not expected to lead to NMD.
We compared breast and ovarian cancer risks between women who had a mutation in a 
specified functional domain compared with all other women who did not have mutations in 
that domain. Mutations in the RING domain were associated with higher breast cancer risks 
and nonsignificant lower ovarian cancer risks than other mutations. These results are 
consistent with the colocation of the BCCR1 (Figure 2) and RING domain. Mutations in the 
BRCT domains were associated with higher breast cancer risk. When analyses were limited 
to mutations conferring NMD, breast cancer risk became significantly associated with 
mutations in the coiled coil domain.
Rebbeck et al. Page 6
JAMA. Author manuscript; available in PMC 2015 August 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
BRCA1: Risks by Category and Function
We observed variability in breast and ovarian cancer risks by mutation class (Table 2 and 
Table 3). For BRCA1-associated breast cancer, most risk groups were associated with higher 
breast cancer risk than the exon 11 nonsense mutation reference group. This result is 
consistent with the data shown in Figure 2 and eTable 2 in the Supplement as it is similar in 
location with the OCCR. Groups with elevated breast cancer risk include all mutations 
leading to NMD (group 1), all premature termination codon mutations except for exon 11 
nonsense mutations (group 2), frame shift and nonsense mutations occurring 53 of c.297 that 
are predicted to lead to NMD and reinitiation (group 3), nonpremature termination codon 
mutations (group 4), all founder mutations (group 5) and the founder mutation c.5266dup C 
(group 5b), missense mutations (group 6) and missense mutations in the RING domain 
(group 6a), missense and in-frame deletions (group 7), all in-frame deletions (group 8), and 
premature termination codon mutations not leading to NMD (group 9). The majority of the 
last group is comprised of c.5266dupC (83%). For BRCA1-associated ovarian cancer (Table 
2), mutations associated with significantly lower ovarian cancer risks compared with the 
reference group included mutations 53 of c.297 (group 3), nonpremature termination codons 
(group 4), founder mutations (group 5, 5a, 5b), missense mutations (group 6, 6a), missense 
and in-frame deletions (group 7), and premature termination codons not leading to NMD 
(group 9).
When comparing mean age differences among women with or without a specific mutation 
category or function, we found small but statistically significant differences. In BRCA1, 
exon 11 mutations were associated with earlier ages at breast and ovarian cancer diagnosis. 
Mutations conferring NMD or premature termination codon were associated with a later age 
at breast cancer diagnosis. Conversely, an earlier age at breast cancer diagnosis was 
associated with nonpremature termination codon mutations and the founder mutations 
(Table 3).
BRCA2: Breast and Ovarian Cancer Cluster Regions
We observed an OCCR (OCCR1) bounded by c.3249 and c.5681, containing c.5946delT 
(6174delT), with statistically significant evidence for a relatively higher ovarian cancer vs 
breast cancer risk among carriers of mutations in bins 6–9 and 11 (Figure 3). OCCR1 is 
explained by both a relative increase in ovarian cancer risk and a relative decrease in breast 
cancer risk, with an increase in ovarian cancer relative to breast cancer risk (RHR = 0.51; 
95% CI, 0.44–0.60; P = 6 × 10−17) (eTable 3 in the Supplement). The putative OCCR1 lies 
within the previously reported OCCR3 and approximately colocalized with the BRC repeats 
within exon 11.17,18,28 A second putative OCCR (OCCR2) outside of the original OCCR 
boundaries also was observed defined by bin 14 (c.6645-c.7471). OCCR2 was associated 
with an increase in ovarian cancer relative to breast cancer risk (RHR = 0.57; 95% CI, 0.41–
0.80; P = .001).
We also observed a relative increase in breast cancer risk and a relative decrease in ovarian 
cancer risk for mutations occurring in the 53 and 33 regions of BRCA2, potentially defining 
multiple BCCRs (ie, BCCR1, BCCR13, and BCCR2) (Figure 3). These 3 regions were 
associated with relatively increased breast cancer risk relative to ovarian cancer risk with 
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RHR = 1.71 (95% CI, 1.06–2.78; P = .03), RHR = 1.63 (95% CI, 1.10–2.40; P = .01), and 
RHR = 2.31 (95% CI, 1.69–3.16; P = .00002), respectively. These regions were associated 
with both increased breast cancer risk and decreased ovarian cancer risk (eTable 3 in the 
Supplement).
We also observed small but statistically significant differences in the mean age at breast 
cancer diagnosis associated with some of these regions. The mean age was greater for 
mutations in OCCR vs mutations not in OCCR (45.0 vs 43.9 years, P < .001; mean 
difference: 1.17; 95% CI, 0.65 to 1.69), lower for mutations in BCCR1 vs mutations not in 
BCCR1 (42.6 vs 44.3 years; P = .004; mean difference: −1.66, 95% CI, −2.80 to −0.53), and 
lower for mutations in BCCR2 vs mutations not in BCCR2 (43.5 vs 44.3 years, P = .04; 
mean difference: −0.80, 95% CI, −1.55 to −0.05).
To complement the prior set of analyses, we also present associations of breast and ovarian 
cancers among groups of BRCA2 mutation carriers defined by known DNA binding domains 
(Table 4). Mutations in the BRC repeats were associated with lower breast cancer risks and 
higher ovarian cancer risks than those mutations not occurring in the BRC repeats consistent 
with their colocation with the OCCR1 (Figure 3).
BRCA2: Risks by Category and Function
For BRCA2-associated cancer, the reference exon 11 mutation group was associated with 
decreased breast cancer risk compared with most other mutation classes (Table 2), consistent 
with colocalization with OCCR1. Compared with the reference group, ovarian cancer risks 
were further reduced among women who carried premature truncation codons (HR = 0.27; 
95% CI, 0.11–0.66). We observed an association with earlier age at breast cancer diagnosis 
with exon 11 mutations and for mutations not conferring NMD (Table 3).
Absolute Risks
To illustrate potential mutation-specific effects on absolute cancer risks, we used the hazard 
ratio estimates to derive approximate absolute risks and 95% confidence intervals, based on 
published estimates for the overall risks of breast and ovarian cancer by age 70 years.26 
These estimates are for illustration and do not represent absolute risk estimates that would 
be required in a genetic counseling setting, as they do not account for noncancer outcomes 
that may influence a woman’s life expectancy, the effects of family history, and nonrandom 
ascertainment of mutation carriers in this sample and depend on assumptions about the 
prevalence of different mutation classes in the population. Using the BRCA1/2 baseline 
breast and ovarian cancer risks of Antoniou et al,26 we estimated risks and confidence 
intervals about these risks (eAppendix 2 in the Supplement). These confidence limits assume 
that the overall risk for a given individual is provided by our estimates and should not be 
interpreted as measuring the overall uncertainty in the absolute risk estimates, as shown in 
Table 5. The overall breast cancer risk for BRCA1 mutation carriers by age 70 years is 59%, 
which increases to 69% (95% CI, 56%–83%) in women who carry a missense mutation, 
Jewish founder mutation, or a mutation that undergoes NMD with reinitiation. The ovarian 
cancer risk in BRCA1 mutation carriers by age 70 years is 34% overall but decreases to 26% 
(95% CI, 10%–43%) among women who carry a founder mutation.
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Discussion
We have identified mutations in BRCA1 or BRCA2 that are associated with significantly 
different risks of breast and ovarian cancers. These mutation-specific risks coincide with 
known or hypothesized functional domains and provide a basis around which accurate risk 
estimates can be generated for women who have inherited a particular BRCA1/2 mutation. 
These results are consistent with prior reports of OCCRs in both BRCA1 and BRCA2 that lie 
in or near exon 11 of both genes.3,5,29,30 Mutations in exon 11 could produce a partial 
BRCA1 protein encoded by the known exon 11 splice variant, while the full-length protein 
is lost by the process of NMD.6 Murine embryos carrying the exon 11–deleted isoform 
survive longer than those that are BRCA1 null, and BRCA1 that has lost exon 11 appear to 
retain partial function.31 Thus, for BRCA1, it is biologically plausible that individuals 
carrying mutations within exon 11 (and the OCCR) may have a different phenotype than 
other mutations. In BRCA2, we have identified OCCRs, coincident with the 8 BRC repeats. 
Mutations in this region appear to be associated with NMD, which would lead to loss of 
BRCA2 expression.7 However, it is possible that there is persistence of an alternatively 
spliced variant of BRCA2, without exon 11 (as for BRCA1), which would represent in-frame 
mutations. In addition, the BRCA2 BRC repeats interact with RAD51, which has been 
consistently shown to be a modifier of BRCA2-associated breast and ovarian cancer risk.32 
Without the BRC repeats, BRCA2 might differ in interactions with RAD51 and lead to 
genotype-phenotype variation. However, the biological basis of the BRCA2 OCCR remains 
speculative, in particular as it does not extend throughout all of exon 11.
In BRCA2, several putative BCCRs were defined. The 33 BCCR coincides approximately 
with mutations occurring in the oligonucleotide binding (OB) fold domains and the tower 
domain. When examined independently, both of these domains were associated with 
relatively elevated breast cancer risk and lower ovarian cancer risk. These mutations in 
BRCA2 would be predicted to undergo NMD. However, it has been demonstrated 
experimentally for only a few mutations, leaving the functional basis unknown.7
We have also identified a decreased risk of ovarian cancer associated with all types of 
mutations predicted not to lead to NMD in BRCA2; the estimated risk was only significant 
for all mutations together and those mutations leading to in-frame splice site or frame shift 
mutations. These mutations all occur after nucleotide 7000 in the C-terminus of BRCA2, 
which includes the DNA binding domains, tower domains, and OB folds.33 These functional 
domains are associated with localization of BRCA2 to sites of double-stranded DNA breaks 
to accomplish repair.33 These data suggest that intact protein may be protective when it 
comes to ovarian cancer risk. However, the number of individuals is small and further 
replication is needed.
A number of limitations of this research may influence the generalizability and translational 
potential of this research. Despite the very large sample size, we were not able to investigate 
some mutation and risk groups with adequate statistical power. Carriers of BRCA2 mutations 
composed a smaller sample set; in particular, the number of women with BRCA2-associated 
ovarian cancers was relatively small. Although all women with a documented disease-
associated mutation in the CIMBA database were included, some populations use screening 
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for founder mutations as a primary method of mutation detection, such as for the 3 
Ashkenazi Jewish mutations. This testing strategy may lead to underreporting of nonfounder 
mutations. As such, some bias in the ascertainment of the full spectrum of mutations could 
have occurred. The ascertainment strategy generally followed clinical and research protocols 
similar across all centers. However, we did not correct for ascertainment, and thus bias may 
have affected some variables (eg, age at diagnosis), which should be interpreted with 
caution. Mutation testing was performed using methods acceptable for clinical practice at 
each center, which was not uniform across all centers.
The present sample set does not reflect the general population of all mutation carriers but 
reflects those women who have undergone genetic testing for BRCA1/2 mutations, a relevant 
population of inference. We have presented the mutations in terms of category or effect, but 
these designations are in some cases extrapolated based on experimental evidence for 
similar mutations. An example is the designation of NMD inferred from mutation location, 
which is based on experimental validation of only a small proportion of the mutations.6,7 
Similarly, inference of protein truncation based on predicted protein-truncating mutations 
without experimental verification may lead to erroneous classification.25 Penetrances that 
are presented here are limited because other factors that are not accounted for here could 
influence these estimates. These factors include family history and competing mortality. 
These risks also depend on knowing the true prevalence of the mutation-specific classes, 
which is likely to be population-specific.
In addition, the present report of more than 32 000 mutation carriers could include some of 
those individuals who were included in the 1995 and 1997 articles that originally reported 
the OCCR.3 It is not possible at this time to know if any of the 32 families carrying BRCA1 
mutations or 25 families carrying BRCA2 originally reported also are included in the present 
sample. However, it is highly unlikely that the small sample of individuals represented in the 
original reports would outweigh a potential null effect among the more than 32 000 
individuals studied here.
This study is the first step in defining differences in risk associated with location and type of 
BRCA1 and BRCA2 mutations. Pending additional mechanistic insights into the observed 
associations, knowledge of mutation-specific risks could provide important information for 
clinical risk assessment among BRCA1/2 mutation carriers, but further systematic studies 
will be required to determine the absolute cancer risks associated with different mutations. It 
is yet to be determined what level of absolute risk change will influence decision making 
among carriers of BRCA1/2 mutations. Additional research will be required to better 
understand what level of risk difference will change decision making and standards of care, 
such as preventive surgery,34 for carriers of BRCA1 and BRCA2 mutations.
Conclusions
Breast and ovarian cancer risks varied by type and location of BRCA1/2 mutations. With 
appropriate validation, these data may have implications for risk assessment and cancer 
prevention decision making among carriers of BRCA1 and BRCA2 mutations.
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Figure 1. Analysis Workflow
Analyses undertaken are listed in the order in which they are presented in the text.
aThe functional domains were the RING, coiled coil, BRCT, BRC, DNA binding, 
oligonucleotide-binding folds, and tower domains.
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Figure 2. Hazard Ratio of Breast Cancer Relative to the Hazard Ratio of Ovarian Cancer by 
BRCA1 Nucleotide Position
The graph shows the ratio of hazard ratios (blue data markers) and 95% CI (error bars) for 
the mutation bins defined across the span of the coding DNA sequence of the BRCA1 gene. 
Black arrowheads under the bins indicate 2 founder mutations of clinical interest in the 
Ashkenazi Jewish population. Regions inferred to be breast cancer cluster regions (BCCRs) 
and ovarian cancer cluster regions (OCCRs) are shown at the bottom. Solid light blue lines 
indicate regions found to be statistically significant; dashed light blue lines indicate regions 
in the same direction of effect that were not statistically significant. eTable 2 in the 
Supplement lists the bins and risks used to define the BCCRs and OCCRs.
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Figure 3. Hazard Ratio of Breast Cancer Relative to the Hazard Ratio of Ovarian Cancer by 
BRCA2 Nucleotide Position
The graph shows the ratio of hazard ratios (blue data markers) and 95% CI (error bars) for 
the mutation bins defined across the span of the coding DNA sequence of the BRCA2 gene. 
The black arrowhead under the bins indicates a founder mutation of clinical interest in the 
Ashkenazi Jewish population. The regions inferred to be breast cancer cluster regions 
(BCCRs) and ovarian cancer cluster regions (OCCRs) are shown at the bottom; the solid 
light blue lines indicate regions found to be statistically significant. eTable 3 in the 
Supplement lists the bins and risks used to define to define the BCCRs and OCCRs.
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